Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study

RB. Postuma, A. Iranzo, M. Hu, B. Högl, BF. Boeve, R. Manni, WH. Oertel, I. Arnulf, L. Ferini-Strambi, M. Puligheddu, E. Antelmi, V. Cochen De Cock, D. Arnaldi, B. Mollenhauer, A. Videnovic, K. Sonka, KY. Jung, D. Kunz, Y. Dauvilliers, F....

. 2019 ; 142 (3) : 744-759. [pub] 20190301

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006582

Grantová podpora
286641 CIHR - Canada
NV16-28914A MZ0 CEP - Centrální evidence projektů

Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, and potentially intervene with neuroprotective therapy. For future neuroprotective trials, it is essential to accurately estimate phenoconversion rate and identify potential predictors of phenoconversion. This study assessed the neurodegenerative disease risk and predictors of neurodegeneration in a large multicentre cohort of iRBD. We combined prospective follow-up data from 24 centres of the International RBD Study Group. At baseline, patients with polysomnographically-confirmed iRBD without parkinsonism or dementia underwent sleep, motor, cognitive, autonomic and special sensory testing. Patients were then prospectively followed, during which risk of dementia and parkinsonsim were assessed. The risk of dementia and parkinsonism was estimated with Kaplan-Meier analysis. Predictors of phenoconversion were assessed with Cox proportional hazards analysis, adjusting for age, sex, and centre. Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis. Overall, 1280 patients were recruited. The average age was 66.3 ± 8.4 and 82.5% were male. Average follow-up was 4.6 years (range = 1-19 years). The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up. The rate of phenoconversion was significantly increased with abnormal quantitative motor testing [hazard ratio (HR) = 3.16], objective motor examination (HR = 3.03), olfactory deficit (HR = 2.62), mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2.11), an abnormal DAT scan (HR = 1.98), colour vision abnormalities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), and age (HR = 1.54). There was no significant predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic symptoms, depression, anxiety, or hyperechogenicity on substantia nigra ultrasound. Among predictive markers, only cognitive variables were different at baseline between those converting to primary dementia versus parkinsonism. Sample size estimates for definitive neuroprotective trials ranged from 142 to 366 patients per arm. This large multicentre study documents the high phenoconversion rate from iRBD to an overt neurodegenerative syndrome. Our findings provide estimates of the relative predictive value of prodromal markers, which can be used to stratify patients for neuroprotective trials.

Brain and Mind Centre University of Sydney Camperdown Australia

Centre d'Études Avancées en Médecine du Sommeil Hôpital du Sacré Cœur de Montréal Montréal Canada

Clinical Neurology Dept of Neuroscience University of Genoa and Polyclinic San Martino Hospital Genoa Italy

Department of Biomedical and Neuromotor Sciences Bellaria Hospital University of Bologna Bologna Italy IRCCS Institute of Neurological Sciences of Bologna Bellaria Hospital Bologna Italy

Department of Biomedical and Neuromotor Sciences University of Bologna Bologna Italy IRCCS Institute of the Neurological Sciences Ospedale Bellaria ASL di Bologna Bologna Italy

Department of Human Genetics McGill University Montreal Canada Department of Neurology and Neurosurgery Montreal Neurological Institute McGill University Montreal Canada

Department of Neurology and Centre of Clinical Neurosciences of the 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Neurology Brigham and Women's Hospital Boston

Department of Neurology Hephata Klinik Schwalmstadt Treysa Germany

Department of Neurology Innsbruck Medical University Innsbruck Austria

Department of Neurology McGill University Montreal General Hospital Montreal Canada

Department of Neurology McGill University Montreal General Hospital Montreal Canada Centre d'Études Avancées en Médecine du Sommeil Hôpital du Sacré Cœur de Montréal Montréal Canada

Department of Neurology Philipps Universität Marburg Germany

Department of Neurosurgery University Medical Center Göttingen

Department of Psychology Université du Québec à Montréal Montreal Quebec Canada

EuroMov University of Montpellier Montpellier France

Harvard Medical School Boston USA

Institute for Sleep Medicine and Neuromuscular Disorders University Hospital Muenster Muenster Germany

Institute of Physiology Charité Universitätsmedizin Berlin Germany

Mayo Clinic Rochester MN USA

Movement Disorders Unit and Division of Sleep Medicine Massachusetts General Hospital Harvard Medical School Boston USA

National Institute of Mental Health Klecany 3rd Faculty of Medicine Charles Unviersity Prague Czech Republic

Neurology Service Hospital Clinic de Barcelona IDIBAPS CIBERNED Barcelona Spain

Neuroscience Research Institute Seoul National University College of Medicine Department of Neurology Seoul National University Hospital Seoul Korea

Nuclear Medicine Department of Health Sciences University of Genoa and Polyclinic San Martino Hospital Genoa Italy

Oxford Parkinson's Disease Centre and Oxford University Oxford UK

Paracelsus Elena Klinik Kassel Germany

Sleep and Neurology Unit Beau Soleil Clinic Montpellier France

Sleep Center Department of Cardiovascular and Neurological Sciences University of Cagliari Italy

Sleep Disorders Center Department of Neurology Scientific Institute Ospedale San Raffaele Vita Salute University Milan Italy

Sleep disorders unit Pitie Salpetriere Hospital and Sorbonne University Paris France

Sleep Unit Department of Neurology Hôpital Gui de Chauliac Montpellier INSERM U1061 Montpellier F 34093 Cedex 5 France

Unit of Sleep Medicine and Epilepsy IRCCS C Mondino Foundation Pavia Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006582
003      
CZ-PrNML
005      
20200522111153.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/brain/awz030 $2 doi
035    __
$a (PubMed)30789229
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Postuma, Ronald B $u Department of Neurology, McGill University, Montreal General Hospital, Montreal, Canada. Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada.
245    10
$a Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study / $c RB. Postuma, A. Iranzo, M. Hu, B. Högl, BF. Boeve, R. Manni, WH. Oertel, I. Arnulf, L. Ferini-Strambi, M. Puligheddu, E. Antelmi, V. Cochen De Cock, D. Arnaldi, B. Mollenhauer, A. Videnovic, K. Sonka, KY. Jung, D. Kunz, Y. Dauvilliers, F. Provini, SJ. Lewis, J. Buskova, M. Pavlova, A. Heidbreder, JY. Montplaisir, J. Santamaria, TR. Barber, A. Stefani, EK. St Louis, M. Terzaghi, A. Janzen, S. Leu-Semenescu, G. Plazzi, F. Nobili, F. Sixel-Doering, P. Dusek, F. Bes, P. Cortelli, K. Ehgoetz Martens, JF. Gagnon, C. Gaig, M. Zucconi, C. Trenkwalder, Z. Gan-Or, C. Lo, M. Rolinski, P. Mahlknecht, E. Holzknecht, AR. Boeve, LN. Teigen, G. Toscano, G. Mayer, S. Morbelli, B. Dawson, A. Pelletier,
520    9_
$a Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, and potentially intervene with neuroprotective therapy. For future neuroprotective trials, it is essential to accurately estimate phenoconversion rate and identify potential predictors of phenoconversion. This study assessed the neurodegenerative disease risk and predictors of neurodegeneration in a large multicentre cohort of iRBD. We combined prospective follow-up data from 24 centres of the International RBD Study Group. At baseline, patients with polysomnographically-confirmed iRBD without parkinsonism or dementia underwent sleep, motor, cognitive, autonomic and special sensory testing. Patients were then prospectively followed, during which risk of dementia and parkinsonsim were assessed. The risk of dementia and parkinsonism was estimated with Kaplan-Meier analysis. Predictors of phenoconversion were assessed with Cox proportional hazards analysis, adjusting for age, sex, and centre. Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis. Overall, 1280 patients were recruited. The average age was 66.3 ± 8.4 and 82.5% were male. Average follow-up was 4.6 years (range = 1-19 years). The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up. The rate of phenoconversion was significantly increased with abnormal quantitative motor testing [hazard ratio (HR) = 3.16], objective motor examination (HR = 3.03), olfactory deficit (HR = 2.62), mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2.11), an abnormal DAT scan (HR = 1.98), colour vision abnormalities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), and age (HR = 1.54). There was no significant predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic symptoms, depression, anxiety, or hyperechogenicity on substantia nigra ultrasound. Among predictive markers, only cognitive variables were different at baseline between those converting to primary dementia versus parkinsonism. Sample size estimates for definitive neuroprotective trials ranged from 142 to 366 patients per arm. This large multicentre study documents the high phenoconversion rate from iRBD to an overt neurodegenerative syndrome. Our findings provide estimates of the relative predictive value of prodromal markers, which can be used to stratify patients for neuroprotective trials.
650    _2
$a senioři $7 D000368
650    _2
$a kohortové studie $7 D015331
650    _2
$a demence $x patofyziologie $7 D003704
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a předpověď $x metody $7 D005544
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a demence s Lewyho tělísky $x patofyziologie $7 D020961
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Parkinsonova nemoc $x patofyziologie $7 D010300
650    _2
$a parkinsonské poruchy $x diagnóza $7 D020734
650    _2
$a polysomnografie $7 D017286
650    _2
$a prodromální symptomy $7 D062706
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a prospektivní studie $7 D011446
650    _2
$a porucha chování v REM spánku $x patofyziologie $7 D020187
650    _2
$a rizikové faktory $7 D012307
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Iranzo, Alex $u Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.
700    1_
$a Hu, Michele $u Oxford Parkinson's Disease Centre (OPDC) and Oxford University, Oxford, UK.
700    1_
$a Högl, Birgit $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Boeve, Bradley F $u Mayo Clinic, Rochester, MN, USA.
700    1_
$a Manni, Raffaele $u Unit of Sleep Medicine and Epilepsy, IRCCS, C.Mondino Foundation, Pavia, Italy.
700    1_
$a Oertel, Wolfgang H $u Department of Neurology, Philipps-Universität, Marburg, Germany.
700    1_
$a Arnulf, Isabelle $u Sleep disorders unit, Pitie-Salpetriere Hospital, IHU@ICM and Sorbonne University, Paris, France.
700    1_
$a Ferini-Strambi, Luigi $u Sleep Disorders Center, Department of Neurology, Scientific Institute Ospedale San Raffaele, Vita-Salute University, Milan, Italy.
700    1_
$a Puligheddu, Monica $u Sleep Center, Department of Cardiovascular and Neurological Sciences, University of Cagliari, Italy.
700    1_
$a Antelmi, Elena $u Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. IRCCS Institute of the Neurological Sciences, Ospedale Bellaria, ASL di Bologna, Bologna, Italy.
700    1_
$a Cochen De Cock, Valerie $u Sleep and Neurology Unit, Beau Soleil Clinic, Montpellier, France; EuroMov, University of Montpellier, Montpellier, France.
700    1_
$a Arnaldi, Dario $u Clinical Neurology, Dept. of Neuroscience (DINOGMI), University of Genoa, and Polyclinic San Martino Hospital, Genoa, Italy.
700    1_
$a Mollenhauer, Brit $u Department of Neurosurgery (C.T.) University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M., C.T. F. S-D.), Kassel, Germany.
700    1_
$a Videnovic, Aleksandar $u Movement Disorders Unit and Division of Sleep Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
700    1_
$a Sonka, Karel $u Department of Neurology and Centre of Clinical Neurosciences of the First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Jung, Ki-Young $u Neuroscience Research Institute, Seoul National University College of Medicine, Department of Neurology, Seoul National University Hospital, Seoul, Korea.
700    1_
$a Kunz, Dieter $u Institute of Physiology Charité-Universitätsmedizin Berlin. Germany.
700    1_
$a Dauvilliers, Yves $u Sleep Unit, Department of Neurology, Hôpital Gui de Chauliac, Montpellier, INSERM U1061, Montpellier, F-34093 Cedex 5 France.
700    1_
$a Provini, Federica $u Department of Biomedical and Neuromotor Sciences, Bellaria Hospital, University of Bologna, Bologna, Italy. IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy.
700    1_
$a Lewis, Simon J $u Brain and Mind Centre University of Sydney, Camperdown, Australia.
700    1_
$a Buskova, Jitka $u National Institute of Mental Health, Klecany, Third Faculty of Medicine, Charles Unviersity, Prague, Czech Republic.
700    1_
$a Pavlova, Milena $u Department of Neurology, Brigham and Women's Hospital, Boston; Harvard Medical School, Boston, USA.
700    1_
$a Heidbreder, Anna $u Institute for Sleep Medicine and Neuromuscular Disorders, University Hospital Muenster, Muenster, Germany.
700    1_
$a Montplaisir, Jacques Y $u Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada.
700    1_
$a Santamaria, Joan $u Sleep and Neurology Unit, Beau Soleil Clinic, Montpellier, France; EuroMov, University of Montpellier, Montpellier, France.
700    1_
$a Barber, Thomas R $u Oxford Parkinson's Disease Centre (OPDC) and Oxford University, Oxford, UK.
700    1_
$a Stefani, Ambra $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a St Louis, Erik K $u Mayo Clinic, Rochester, MN, USA.
700    1_
$a Terzaghi, Michele $u Unit of Sleep Medicine and Epilepsy, IRCCS, C.Mondino Foundation, Pavia, Italy.
700    1_
$a Janzen, Annette $u Department of Neurology, Philipps-Universität, Marburg, Germany.
700    1_
$a Leu-Semenescu, Smandra $u Sleep disorders unit, Pitie-Salpetriere Hospital, IHU@ICM and Sorbonne University, Paris, France.
700    1_
$a Plazzi, Guiseppe $u Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. IRCCS Institute of the Neurological Sciences, Ospedale Bellaria, ASL di Bologna, Bologna, Italy.
700    1_
$a Nobili, Flavio $u Clinical Neurology, Dept. of Neuroscience (DINOGMI), University of Genoa, and Polyclinic San Martino Hospital, Genoa, Italy.
700    1_
$a Sixel-Doering, Friederike $u Department of Neurosurgery (C.T.) University Medical Center, Göttingen; Paracelsus-Elena-Klinik (B.M., C.T. F. S-D.), Kassel, Germany.
700    1_
$a Dusek, Petr $u Department of Neurology and Centre of Clinical Neurosciences of the First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Bes, Frederik $u Institute of Physiology Charité-Universitätsmedizin Berlin. Germany.
700    1_
$a Cortelli, Pietro $u Department of Biomedical and Neuromotor Sciences, Bellaria Hospital, University of Bologna, Bologna, Italy. IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy.
700    1_
$a Ehgoetz Martens, Kaylena $u Brain and Mind Centre University of Sydney, Camperdown, Australia.
700    1_
$a Gagnon, Jean-Francois $u Department of Psychology, Université du Québec à Montréal, Montreal, Quebec, Canada.
700    1_
$a Gaig, Carles $u Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.
700    1_
$a Zucconi, Marco $u Sleep Disorders Center, Department of Neurology, Scientific Institute Ospedale San Raffaele, Vita-Salute University, Milan, Italy.
700    1_
$a Trenkwalder, Claudia $u Clinical Neurology, Dept. of Neuroscience (DINOGMI), University of Genoa, and Polyclinic San Martino Hospital, Genoa, Italy.
700    1_
$a Gan-Or, Ziv $u Department of Human Genetics, McGill University, Montreal, Canada. Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada.
700    1_
$a Lo, Christine $u Oxford Parkinson's Disease Centre (OPDC) and Oxford University, Oxford, UK.
700    1_
$a Rolinski, Michal $u Oxford Parkinson's Disease Centre (OPDC) and Oxford University, Oxford, UK.
700    1_
$a Mahlknecht, Philip $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Holzknecht, Evi $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Boeve, Angel R $u Mayo Clinic, Rochester, MN, USA.
700    1_
$a Teigen, Luke N $u Mayo Clinic, Rochester, MN, USA.
700    1_
$a Toscano, Gianpaolo $u Unit of Sleep Medicine and Epilepsy, IRCCS, C.Mondino Foundation, Pavia, Italy.
700    1_
$a Mayer, Geert $u Department of Neurology, Hephata Klinik, Schwalmstadt-Treysa, Germany.
700    1_
$a Morbelli, Silvia $u Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genoa and Polyclinic San Martino Hospital, Genoa, Italy.
700    1_
$a Dawson, Benjamin $u Department of Neurology, McGill University, Montreal General Hospital, Montreal, Canada.
700    1_
$a Pelletier, Amelie $u Department of Neurology, McGill University, Montreal General Hospital, Montreal, Canada. Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada.
773    0_
$w MED00009356 $t Brain : a journal of neurology $x 1460-2156 $g Roč. 142, č. 3 (2019), s. 744-759
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30789229 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200522111151 $b ABA008
999    __
$a ok $b bmc $g 1525440 $s 1096638
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 142 $c 3 $d 744-759 $e 20190301 $i 1460-2156 $m Brain $n Brain $x MED00009356
GRA    __
$a 286641 $p CIHR $2 Canada
GRA    __
$a NV16-28914A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace